Design Therapeutics, Inc.

NasdaqGS:DSGN Stock Report

Market Cap: US$211.3m

Design Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Design Therapeutics has a total shareholder equity of $277.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $289.6M and $12.0M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$281.80m
EquityUS$277.69m
Total liabilitiesUS$11.96m
Total assetsUS$289.64m

Recent financial health updates

Recent updates

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Mar 15
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Nov 16
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Jun 06
Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Feb 09
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Oct 25
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Design Therapeutics GAAP EPS of -$0.27 misses by $0.02

Aug 08

We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate

Jul 02
We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Mar 18
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Dec 03
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Aug 18
Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Design Therapeutics expands board of directors

Jun 07

Design Therapeutics EPS misses by $0.24

May 10

Financial Position Analysis

Short Term Liabilities: DSGN's short term assets ($284.6M) exceed its short term liabilities ($9.6M).

Long Term Liabilities: DSGN's short term assets ($284.6M) exceed its long term liabilities ($2.3M).


Debt to Equity History and Analysis

Debt Level: DSGN is debt free.

Reducing Debt: DSGN had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DSGN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: DSGN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 50% each year


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.